|
|
基因多态性与他汀类药物疗效相关性研究进展
|
Abstract:
遗传变异导致了个体间药代动力学和药效学差异，这可能会影响对治疗药物的反应。尽管有研究表明几种候选基因与他汀类药物疗效相关，但尚未出现指导他汀类药物治疗的临床相关药物基因组学测试，本文以可能与他汀抵抗相关的基因做一综述。
Genetic variation leads to individual differences in pharmacokinetics and pharmacodynamics, which may affect the response to therapeutic drugs. Although some studies have shown that several candidate genes are associated with the efficacy of statins, there are no clinically relevant phar-macogenomic tests that guide the treatment of statins. This article reviews the genes that may be related to statin resistance.
| [1] | Wang, W., Jiang, B., Sun, H., et al. (2017) Prevalence, Incidence, and Mortality of Stroke in China: Results from a Na-tionwide Population-Based Survey of 480？687 Adults. Circulation, 135, 759-771.
https://doi.org/10.1161/CIRCULATIONAHA.116.025250 |
| [2] | Borén, J. and Williams, K.J. (2016) The Central Role of Arterial Retention of Cholesterol-Rich Apolipoprotein-B-Containing Lipoproteins in the Pathogenesis of Athero-sclerosis: A Triumph of Simplicity. Current Opinion in Lipidology, 27, 473-483. https://doi.org/10.1097/MOL.0000000000000330 |
| [3] | Libby, P., Buring, J.E., Badimon, L., et al. (2019) Athero-sclerosis. Nature Reviews Disease Primers, 5, Article No. 56.
https://doi.org/10.1038/s41572-019-0106-z |
| [4] | Ference, B.A., Ginsberg, H.N., Graham, I., et al. (2017) Low-Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease. 1. Evidence from Genetic, Epidemiologic, and Clinical Studies. A Consensus Statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38, 2459-2472.
https://doi.org/10.1093/eurheartj/ehx144 |
| [5] | Nordestgaard, B.G., Chapman, M.J., Humphries, S.E., et al. (2013) Familial Hypercholesterolaemia Is Underdiagnosed and Undertreated in the General Population: Guidance for Clinicians to Prevent Coronary Heart Disease: Consensus Statement of the European Atherosclerosis Society. European Heart Journal, 34, 3478-3490.
https://doi.org/10.1093/eurheartj/eht273 |
| [6] | Amarenco, P. and Labreuche, J. (2009) Lipid Management in the Pre-vention of Stroke: Review and Updated Meta-Analysis of Statins for Stroke Prevention. The Lancet Neurology, 8, 453-463.
https://doi.org/10.1016/S1474-4422(09)70058-4 |
| [7] | Baigent, C., Keech, A., Kearney, P.M., et al. (2005) Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from 90,056 Participants in 14 Ran-domised Trials of Statins. Lancet, 366, 1267-1278.
https://doi.org/10.1016/S0140-6736(05)67394-1 |
| [8] | Guan, Z.-W., Wu, K.-R., Li, R., et al. (2019) Pharmaco-genetics of Statins Treatment: Efficacy and Safety. Journal of Clinical Pharmacy and Therapeutics, 44, 858-867. https://doi.org/10.1111/jcpt.13025 |
| [9] | Istvan, E.S. and Deisenhofer, J. (2001) Structural Mechanism for Statin In-hibition of HMG-CoA Reductase. Science, 292, 1160-1164. https://doi.org/10.1126/science.1059344 |
| [10] | Sirtori, C.R. (2014) The Pharmacology of Statins. Pharmacological Research, 88, 3-11.
https://doi.org/10.1016/j.phrs.2014.03.002 |
| [11] | Brown, M.S. and Goldstein, J.L. (1997) The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor. Cell, 89, 331-340. https://doi.org/10.1016/S0092-8674(00)80213-5 |
| [12] | 任新宇, 周玉杰, 马茜. 他汀类药物作用机制的研究进展[J]. 中国医药, 2016, 11(3): 442-447. |
| [13] | Ridker, P.M., Danielson, E., Fonseca, F.A., et al. (2008) Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine, 359, 2195-2207.
https://doi.org/10.1056/NEJMoa0807646 |
| [14] | Downs, J.R., Clearfield, M., Weis, S., et al. (1998) Primary Preven-tion of Acute Coronary Events with Lovastatin in Men and Women with Average Cholesterol Levels: Results of AFCAPS/TexCAPS. JAMA, 279, 1615-1622.
https://doi.org/10.1001/jama.279.20.1615 |
| [15] | Mangravite, L.M., Thorn, C.F. and Krauss, R.M. (2006) Clinical Implications of Pharmacogenomics of Statin Treatment. The Pharmacogenomics Journal, 6, 360-374. https://doi.org/10.1038/sj.tpj.6500384 |
| [16] | Krauss, R.M., Mangravite, L.M., Smith, J.D., et al. (2008) Variation in the 3-Hydroxyl-3-Methylglutaryl Coenzyme A Reductase Gene Is Associated with Racial Differences in Low-Density Lipoprotein Cholesterol Response to Simvastatin Treatment. Circulation, 117, 1537-1544. https://doi.org/10.1161/CIRCULATIONAHA.107.708388 |
| [17] | Donnelly, L.A., Doney, A.S., Dannfald, J., et al. (2008) A Paucimorphic Variant in the HMG-CoA Reductase Gene Is Associated with Lipid-Lowering Response to Statin Treatment in Diabetes: A GoDARTS Study. Pharmacogenetics and Genomics, 18, 1021-1026. https://doi.org/10.1097/FPC.0b013e3283106071 |
| [18] | Cuevas, A., Fernández, C., Ferrada, L., et al. (2016) HMGCR rs17671591 SNP Determines Lower Plasma LDL-C after Atorvastatin Therapy in Chilean Individuals. Basic & Clinical Pharmacology & Toxicology, 118, 292-297.
https://doi.org/10.1111/bcpt.12493 |
| [19] | Cano-Corres, R., Candás-Estébanez, B., Padró-Miquel, A., et al. (2018) Influence of 6 Genetic Variants on the Efficacy of Statins in Patients with Dyslipidemia. Journal of Clinical Laboratory Analysis, 32, e22566.
https://doi.org/10.1002/jcla.22566 |
| [20] | Medina, M.W., Gao, F., Ruan, W., Rotter, J.I. and Krauss, R.M. (2008) Alternative Splicing of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Is Associated with Plasma Low-Density Lipoprotein Cholesterol Response to Simvastatin. Circulation, 118, 355-362. https://doi.org/10.1161/CIRCULATIONAHA.108.773267 |
| [21] | Bays, H., Cohen, D.E., Chalasani, N. and Harri-son, S.A. (2014) An Assessment by the Statin Liver Safety Task Force: 2014 Update. Journal of Clinical Lipidology, 8, S47-S57. https://doi.org/10.1016/j.jacl.2014.02.011 |
| [22] | Talameh, J.A. and Kitzmiller, J.P. (2014) Pharmacogenet-ics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants. Journal of Pharmacogenomics & Pharmacoproteomics, 5, Article ID: 100012. https://doi.org/10.4172/2153-0645.1000128 |
| [23] | Sivkov, A., Chernus, N., Gorenkov, R., et al. (2021) Relationship between Genetic Polymorphism of Drug Transporters and the Efficacy of Rosuvastatin, atorvastatin and simvastatin in Patients with Hyperlipidemia. Lipids in Health and Disease, 20, Article No. 157. https://doi.org/10.1186/s12944-021-01586-7 |
| [24] | Tudorache, I.F., Trusca, V.G., and Gafencu, A.V. (2017) Apolipoprotein E—A Multifunctional Protein with Implications in Various Pathologies as a Result of Its Structural Fea-tures. Computational and Structural Biotechnology Journal, 15, 359-365. https://doi.org/10.1016/j.csbj.2017.05.003 |
| [25] | 刘艳辉, 董婧, 陆燕, 等. SLCO1B1521 T>C和APOE基因多态性对阿托伐他汀调脂疗效及安全性的影响[J]. 药学实践杂志, 2021, 39(3): 245-248. |
| [26] | 高辉, 王杨, 陈婉婷, 卫波. SLCO1B1和APOE基因多态性与他汀类药物疗效的相关性[J]. 实用医学杂志, 2019, 35(14): 2300-2303. |
| [27] | Mahley, R.W. (2016) Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Me-tabolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 36, 1305-1315. https://doi.org/10.1161/ATVBAHA.116.307023 |
| [28] | Neumann, J., Rose-Sperling, D and Hellmich, U.A. (2017) Diverse Relations between ABC Transporters and Lipids: An Overview. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1859, 605-618.
https://doi.org/10.1016/j.bbamem.2016.09.023 |
| [29] | Fukunaga, K., Nakagawa, H., Ishikawa, T., Kubo, M. and Mushiroda, T. (2016) ABCB1 Polymorphism Is Associated with Atorvastatin-Induced Liver Injury in Japanese Popula-tion. BMC Genomic Data, 17, Article No. 79.
https://doi.org/10.1186/s12863-016-0390-5 |
| [30] | Hoenig, M.R., Walker, P.J., Gurnsey, C., Beadle, K. and Johnson, L. (2011) The C3435T Polymorphism in ABCB1 Influences Atorvastatin Efficacy and Muscle Symptoms in a High-Risk Vascular Cohort. Journal of Clinical Lipidology, 5, 91-96. https://doi.org/10.1016/j.jacl.2011.01.001 |
| [31] | Gu, G.-L., Xu, X.-L., Yang, Q.-Y. and Zeng, R.-L. (2014) Effect of CETP Polymorphism on Atorvastatin Lipid-Regulating Effect and Clinical Prognosis of Patients with Coronary Heart Disease. Medical Science Monitor, 20, 2824-2829. https://doi.org/10.12659/MSM.892711 |
| [32] | Gao, J., Cong, H.L., Mao, Y.M., et al. (2013) Influence of CETP Gene-629C/A Polymorphism on the Efficacy of Atorvastatin Treatment and Clinical Outcome. Chinese Journal of Medi-cal Genetics, 30, 553-558. (In Chinese) |
| [33] | Rader, D.J. and Degoma, E.M. (2014) Future of Cholesteryl Ester Trans-fer Protein Inhibitors. Annual Review of Medicine, 65, 385-403. https://doi.org/10.1146/annurev-med-050311-163305 |
| [34] | Kitzmiller, J.P., Binkley, P.F., Pandey, S.R., et al. (2013) Statin Pharmacogenomics: Pursuing Biomarkers for Predicting Clinical Outcomes. Discovery Medicine, 16, 45-51. |
